ASTRAZENECA PLC Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-03-04: Form 6-K; Period of report 2021-03-04; Description DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES; Document a2348r.htm.
- 2021-03-03: Form 6-K; Period of report 2021-03-03; Description US COURT DECISION FAVOURS SYMBICORT PATENTS; Document a9930q.htm.
- 2021-03-02: Form 6-K; Period of report 2021-03-02; Description FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE; Document a7831q.htm.
- 2021-03-01: Form 6-K; Period of report 2021-03-01; Description TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL; Document a7273q.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2021-03-04 | 6-K | 2021-03-04 | DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES | a2348r.htm |
| 2021-03-03 | 6-K | 2021-03-03 | US COURT DECISION FAVOURS SYMBICORT PATENTS | a9930q.htm |
| 2021-03-02 | 6-K | 2021-03-02 | FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE | a7831q.htm |
| 2021-03-01 | 6-K | 2021-03-01 | TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL | a7273q.htm |
| 2021-02-22 | 6-K | 2021-02-22 | VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US | a8610p.htm |
| 2021-02-17 | 6-K | 2021-02-17 | LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA | a3947p.htm |
| 2021-02-16 | 6-K | 2021-02-16 | FILING OF FORM 20-F WITH SEC | a2477p.htm |
| 2021-02-16 | 6-K | 2021-02-16 | DIRECTOR/PDMR SHAREHOLDING | a1466p.htm |
| 2021-02-16 | 6-K | 2021-02-16 | ANNUAL FINANCIAL REPORT | a1125p.htm |
| 2021-02-11 | 6-K | 2021-02-11 | ASTRAZENECA NON-EXECUTIVE BOARD CHANGES | a6931o.htm |
| 2021-02-11 | 6-K | 2021-02-11 | AZN: FULL-YEAR 2020 RESULTS | a6964o.htm |
| 2021-02-10 | 6-K | 2021-02-10 | DIVESTMENT OF CRESTOR IN EUROPE COMPLETED | a5864o.htm |
| 2021-02-05 | 6-K | 2021-02-05 | UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI | a1317o.htm |
| 2021-02-04 | 6-K | 2021-02-04 | FORXIGA APPROVED IN CHINA FOR HEART FAILURE | a9857n.htm |
| 2021-02-01 | 6-K | 2021-02-01 | TOTAL VOTING RIGHTS | a5749n.htm |
| 2021-02-01 | 6-K | 2021-02-01 | ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING | a5672n.htm |
| 2021-02-01 | 6-K | 2021-02-01 | COVID-19 VACCINE AUTHORISED FOR USE BY THE EU | a5067n.htm |
| 2021-01-29 | 6-K | 2021-01-29 | COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU | a4213n.htm |
| 2021-01-26 | 6-K | 2021-01-26 | BLOCK LISTING APPLICATION | a9585m.htm |
| 2021-01-26 | 6-K | 2021-01-26 | SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA | a8902m.htm |
| 2021-01-25 | 6-K | 2021-01-25 | CALQUENCE APPROVED IN JAPAN FOR CLL | a7291m.htm |
| 2021-01-25 | 6-K | 2021-01-25 | CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB | a7287m.htm |
| 2021-01-20 | 6-K | 2021-01-20 | ENHERTU APPROVED IN THE EU FOR BREAST CANCER | a2825m.htm |
| 2021-01-19 | 6-K | 2021-01-19 | ENHERTU APPROVED IN THE US FOR GASTRIC CANCER | a9827l.htm |
| 2021-01-15 | 6-K | 2021-01-15 | IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO | a8329l.htm |
| 2021-01-06 | 6-K | 2021-01-06 | FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR | a7320k.htm |
| 2021-01-04 | 6-K | 2021-01-04 | TOTAL VOTING RIGHTS | a4805k.htm |
| 2021-01-04 | 6-K | 2021-01-04 | ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED | a3969k.htm |